Acute Metabolic Effects of Estradiol

Status Completed

Clinical Trial Summary

Estradiol promotes and maintains the typical female phenotype characterized by subcutaneous fat accumulation. There is evidence to suggest that this effect relies on the ability of estradiol to increase the amount of anti-lipolytic α2A-adrenergic receptors, but whether this requires long-term exposure to estradiol or is the result of an immediate effect is not clear. Objective: To study acute effects of a single dose (4 mg) of 17β-estradiol on regional and systemic lipolysis.

Clinical Trial Description

Estradiol affects muscle and fat distribution, and thereby lipid metabolism. A reduction in muscle power is seen after menopause, readily counteracted by female hormone therapy (HT). Treatment with HT through months to previously untreated postmenopausal women, or hormone replacement therapy (HRT) to women with Turner syndrome, increases muscle mass and reduces fat mass. HT in postmenopausal women furthermore prevents fat accumulation and increases lipoprotein lipase activity and lipolysis to an extent comparable to premenopausal women. In contrast, it has also been shown that estradiol may actually attenuate lipolysis during basal as well as catecholamine stimulated conditions. In addition, one study found whole body fat metabolism to be lower during treatment with estradiol than without, and reduced lipolysis is present in postmenopausal women during treatment with estradiol, along with an increased number of α-adrenergic receptors and a decreased number of β-adrenergic receptors.

It is not clear whether the lipolytic effect of estradiol happens acutely or is dependent on chronic exposure. Moreover, regional differences in the pharmacodynamics of estradiol have not been assessed. Finally, effects on skeletal muscle have never been examined.

The purpose of the present study was 1) by microdialysis to quantify the regional production of glycerol in two tissues (muscle and fat), and in two regions (abdominal and femoral). 2) To quantify the whole-body lipolytic effect of estradiol, and 3) in biopsies to study intracellular mechanisms behind the action of estradiol. ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Postmenopause

Clinical Trial Details

NCT number	NCT00435175
Study type	Interventional
Source	University of Aarhus
Contact
Status	Completed
Phase	N/A
Start date	June 2005
Completion date	July 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05448079` - The Effect of Sexual Counseling Given According to the PLISSIT Model on FSFI, MAS and SQOL-F of Postmenopausal Women	N/A
Completed	`NCT00745173` - Study Evaluating Premarin and Bazedoxifene Potential Interaction	Phase 1
Completed	`NCT00913926` - Effects of Wellnara on Climacteric Symptoms	N/A
Completed	`NCT00550433` - Study Evaluating Bazedoxifene/CE in Postmenopausal Women	Phase 1
Completed	`NCT00515593` - PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)	N/A
Completed	`NCT00381251` - Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.	Phase 1
Completed	`NCT00484107` - Tolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women	Phase 4
Completed	`NCT00185328` - Efficacy and Tolerability of Angeliq in Thai Women	Phase 4
Completed	`NCT00023543` - Reduction of Triglycerides in Women on Hormone Replacement Therapy	Phase 2
Completed	`NCT00006407` - Sex Steroid Hormones and Risk of CHD in Women	N/A
Completed	`NCT00152282` - A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women	Phase 2
Completed	`NCT00006539` - Thrombotic, Inflammatory & Gene Markers of CVD in Women	N/A
Completed	`NCT00010712` - Effects of Black Cohosh on Menopausal Hot Flashes	Phase 2
Completed	`NCT00005515` - Mutations, Hormone Therapy (HRT) and Venous Thromboembolism	N/A
Completed	`NCT00001752` - Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women	Phase 2
Completed	`NCT00000481` - Women's Health Trial: Feasibility Study in Minority Populations	Phase 3
Completed	`NCT00000466` - Postmenopausal Estrogen/Progestin Interventions (PEPI)	Phase 3
Completed	`NCT00543634` - Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women	Phase 1
Completed	`NCT06115577` - Endometrial Tissues and Mononuclear Cells Receptivity in Pathogenesis of Endometrial Proliferative Processes
Completed	`NCT01556737` - Effect of Two Different Isoflavone Supplement Preparations on Gene-expression in Postmenopausal Women	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.